All In Biotech

Drug Trial Radar · NCT00958438

PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)

A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy

Last checked: Nov 20, 2026Latest source record: Apr 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 248 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

248

Actual

Start

Jul 2009

Primary completion

Dec 2010

Study completion Dec 2010

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Aug 13, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical research study was to determine the safety and effectiveness of an experimental drug called rilonacept in participants with gout who are beginning allopurinol treatment for gout. Participants will participate in this study for approximately 22 weeks. Rilonacept was being studied for use in preventing allopurinol-induced gout flares.

Conditions

  • Gout

Interventions

  • PlaceboDrug

    Placebo loading dose followed by placebo subcutaneous (SC) injection (2 mL) once a week for 16 weeks.

  • RilonaceptDrug

    Rilonacept 160 mg SC loading dose followed by Rilonacept 80 mg/2 mL SC injections once a week for 16 weeks.

  • RilonaceptDrug

    Rilonacept 320 mg SC loading dose followed by Rilonacept 160 mg/2 mL SC injections once a week for 16 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Gout Flares Per Participant Assessed From Day 1 to Day 113 (Week 16)Time frame: Day 1 to Day 113 (Week 16)

Locations

61 sites in 5 countries. Site status is shown where the registry gives one.

  • Site not named

    Berlin, Germany

  • Site not named

    Essen, Germany

  • Site not named

    Goch, Germany

  • Site not named

    Hamburg, Germany

  • Site not named

    Kassel, Germany

  • Site not named

    Künzing, Germany

  • Site not named

    Lollar, Germany

  • Site not named

    Magdeburg, Germany

  • Site not named

    München, Germany

  • Site not named

    Rhaunen, Germany

  • Site not named

    Siegen, Germany

  • Site not named

    Ahmedabad, India

  • Site not named

    Bangalore, India

  • Site not named

    Gandhinagar, India

  • Site not named

    Hyderabaad, India

  • Site not named

    Kolkata, India

  • Site not named

    Mangalore, India

  • Site not named

    Pune, India

  • Site not named

    Secunderabad, India

  • Site not named

    Vadodara, India

  • Site not named

    Varanasi, India

  • Site not named

    Denpasar, Indonesia

  • Site not named

    Jakarta, Indonesia

  • Site not named

    Kemerdekaan, Indonesia

  • Site not named

    Palembang, Indonesia

  • Site not named

    Semarang, Indonesia

  • Site not named

    South Sulawesi, Indonesia

  • Site not named

    West Java, Indonesia

  • Site not named

    Yogyakarta, Indonesia

  • Site not named

    Benoni, South Africa

  • Site not named

    Bloemfontein, South Africa

  • Site not named

    Breyten, South Africa

  • Site not named

    Cape Town, South Africa

  • Site not named

    Dundee, South Africa

  • Site not named

    Durban, South Africa

  • Site not named

    Durban North, South Africa

  • Site not named

    eManzimtoti, South Africa

  • Site not named

    Gauteng, South Africa

  • Site not named

    Johannesburg, South Africa

  • Site not named

    Kempton Park, South Africa

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.